NCT04639986: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- MBC

Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have progressed on at least 2, and no more than 4, prior systemic chemotherapy regimens for metastatic breast cancer
Exclusions: Patients with known brain metastases; Patients that have not been treated with at least 1 taxane in any setting, & at least 1 prior anticancer hormonal treatment in any setting

Comments are closed.

Up ↑